Company news
Connect Biopharma Holdings Limited (NASDAQ:CNTB) news
Connect Biopharma Holdings Limited news releases on 6ix. Latest, Dec 11, 2023: Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial…
Press releases — page 2
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
December 10, 2023
Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart
November 22, 2023
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
November 20, 2023
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
November 20, 2023
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
September 11, 2023
Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis
May 31, 2023
Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update
April 10, 2023
Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms
March 17, 2023
Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions
March 16, 2023
Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting
March 5, 2023
Connect Biopharma Provides Business and Clinical Development Program Update
December 29, 2022
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
December 1, 2022
Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
October 3, 2022
Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis
October 2, 2022
Connect Biopharma Reports First Half 2022 Financial Results and Provides Business Update
September 12, 2022
Connect Biopharma to Report First Half 2022 Financial Results on September 13
August 31, 2022
Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose Study
August 29, 2022
Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022
July 10, 2022
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
May 2, 2022
Connect Biopharma Reports Full Year 2021 Financial Results and Provides Business Update
March 30, 2022
Connect Biopharma Appoints Autoimmune and Immunology Expert Chin Lee, MD, MPH as Chief Medical Officer
February 28, 2022
Connect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis
January 4, 2022
Connect Biopharma to Host Conference Call on January 5 at 8:30 AM ET to Review Detailed Data from the Global Phase 2b Trial of CBP-201
January 3, 2022
Connect Biopharma Expands Executive Leadership Team with Hire of Chief Financial Officer
November 21, 2021
Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis
November 18, 2021
Connect Biopharma Reports Positive Top-Line Results from the Global Phase 2 Clinical Trial of CBP-201 in Patients with Moderate-to-Severe Atopic Dermatitis
November 17, 2021
Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating CBP-201 in Adult Patients with Chronic Rhinosinusitis with Nasal Polyps
September 7, 2021
Connect Biopharma Announces First Patient Dosed in China Pivotal Trial Evaluating CBP-201 in Adults with Moderate-to-Severe Atopic Dermatitis
September 1, 2021
Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results
August 30, 2021
Connect Biopharma Hires General Counsel & Chief Compliance Officer and Appoints a New Board Member
August 22, 2021
Connect Biopharma Announces First Subject Dosed in Phase I Trial Evaluating Safety, Tolerability and Pharmacokinetic Profile of CBP-174 in Healthy Adult Subjects
May 24, 2021
Connect Biopharma Announces First Patient Dosed in Phase 2 Trial Evaluating CBP-201 in Adults with Moderate-to-Severe Persistent Asthma
May 11, 2021
Connect Biopharma Completes Enrollment of CBP-201 Global Phase 2 Clinical Trial in Moderate-to-Severe Atopic Dermatitis
April 7, 2021
Connect Biopharma Holdings Limited Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
March 22, 2021